Clostridium Difficile Diagnostic and Treatment Market Size, Share, And Trends Analysis By Product Type: (Vancomycin, Metronidazole, Bezlotoxumab, Fidaxomicin) By Test: (Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Enzyme Immunoassays) By Distribution Channel: (Hospitals & Clinics, Diagnostic Laboratories, Pharmacies) Based On Region, And Segment Forecasts, 2022 - 2028

  • Report ID: BMRC 253 | Number of pages: 200 | Published Date: Apr 2022

    Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Clostridium Difficile Diagnostic and Treatment Market Size, Share, And Trends Analysis By Product Type: (Vancomycin, Metronidazole, Bezlotoxumab, Fidaxomicin) By Test: (Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Enzyme Immunoassays) By Distribution Channel: (Hospitals & Clinics, Diagnostic Laboratories, Pharmacies) Based On Region, And Segment Forecasts, 2022 - 2028 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Global Clostridium Difficile Diagnostic and Treatment Market was valued at USD 2,571.22 million in 2021 and it is expected to reach USD 5,663.87 million by 2028, with a CAGR of 11.9% during the forecast period.

Global Clostridium Difficile Diagnostic and Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Increased prevalence of Clostridium difficile infection, robust product pipeline of different therapies for the treatment and growing R & D activities for effective treatments are anticipated to drive the growth of Global Clostridium Difficile Diagnostic and Treatment Market.

Scope of Clostridium Difficile Diagnostic and Treatment Market Report:-

Clostridium difficile is caused by clostridium difficile bacteria and it is the most common infection among older adults. More than 80% of C. difficile deaths occur in people older than 65 or more. Clostridium difficile colitis results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics. Clostridium difficile is caused by clostridium difficile bacteria which is common infection among older adults. Growing prevalence of healthcare-associated infections has been one of the major drivers of the global clostridium difficile diagnostics and treatment market. In 2011 C. difficile was estimated to cause about half a million infections among adults in United States due to which ~29,000 people died within 30 days of the initial diagnosis. During the study of Global Clostridium Difficile Diagnostics and Treatment market, we have considered clostridium difficile diagnostics and treatment product type and test type to analyze the market.

Clostridium difficile infection caused due to the spore-forming bacterium Clostridium difficile. Its major symptoms include; fever, watery diarrhea, nausea, and pain in stomach. Difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Generally, clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic acid amplification tests for Clostridium difficile toxin genes or endoscopy. Various drugs such as metronidazole, fidoxamycin and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in abdominal wall, patients undergo surgery for removal of infected portion.

Report Analysis Details
Historical data 2018 - 2021
Forecast Period 2022 - 2028
Market Size in 2021: USD 2,571.22 Million
Base year considered 2021
Forecast Period CAGR %:

11.9%

Market Size Expected in 2028: USD 5,663.87 Million
Tables, Charts & Figures: 175
Pages 200
Key Players/Companies Merck & Co., Inc., Baxter International Inc., Sanofi S.A., Pfizer limited, Novartis, Astellas Pharma Inc., Eli Lilly and Company, AstraZeneca Plc., Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.), and Mylan N.V. and others
Segments Covered By Product Type, By Test, By Distribution Channel
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

The COVID-19 has shown a decline impact on the growth of the global Clostridium Difficile Diagnostic and Treatment Market owing to the increased burden on the healthcare sector globally. It has disturbed the supply chain network of the market. Thus, due to all these factors, Covid-19 has limited the market growth.

Global Clostridium Difficile Diagnostic and Treatment Market Segmentation:

Global clostridium difficile diagnostic and treatment market is segmented on the basis of product type, test, distribution channel and region & country level. Based upon product type, global clostridium difficile diagnostic and treatment market is classified into metronidazole, vancomycin, fidaxomicin and bezlotoxumab and others. Based upon test type, the market is divided into real-time polymerase chain reaction (RT-PCR), nucleic amplification tests (NAAT), enzyme immunoassays and others. Based on distribution channel, the global clostridium difficile diagnostic and treatment market is classified into hospitals & clinics, diagnostic laboratories and pharmacies.

By Product Type:

  • Vancomycin
  • Metronidazole
  • Bezlotoxumab
  • Fidaxomicin

By Test:

  • Real-Time Polymerase Chain Reaction (RT-PCR)
  • Nucleic Amplification Tests (NAAT)
  • Enzyme Immunoassays
  • Others

By Distribution Channel:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Pharmacies

Key Players for Global Clostridium Difficile Diagnostic and Treatment Report:

Some major key players for Global Clostridium Difficile Diagnostic and Treatment report cover prominent players like

  • Merck & Co., Inc.
  • Baxter International Inc.
  • Sanofi S.A.
  • Pfizer Limited
  • Novartis
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • AstraZeneca Plc.
  • Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.)
  • Mylan N.V.
  • others.

News: Researchers Identified Starting Point for Designing Drugs that Cure Clostridium difficile

On January 2nd, 2020; a published paper in PNAS, details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure Clostridium difficile (C. diff).  Through investigating a type of toxin released by the most dangerous strains of C. diff, researchers now have a map for developing drugs that had block the toxin and prevent the bacteria from entering human cells. A combination of cryogenic electron microscopy, X-ray crystallography, nuclear magnetic resonance, and small angle X-ray scattering helps to observe and identify the C. diff toxin's structure and mode of action. Believing that it was a binary toxin needing two components to function, researchers thought it could be similar to anthrax toxin, and sought to characterize what made the C. diff toxin different from anthrax.

Increased Prevalence of Clostridium difficile Infection, Robust Product Pipeline of Different Therapies for the Treatment and Growing R & D Activities for Effective Treatments are Some of the Major Factors Driving the Market Growth

The major factor driving the growth of global clostridium difficile diagnostic and treatment is increased prevalence of clostridium difficile infection. In US each year three million new cases of C difficile colitis occur; as many as 10% of patients hospitalized for at least 2 days are affected. In some case series suggest that C difficile colitis has become more common and potentially more pathogenic. An increased incidence of C difficile colitis was reported in hospitalized patients in Pittsburgh, Pennsylvania, and Portland, Oregon. Similarly, population-based data from Quebec revealed an increased incidence of C difficile colitis and an increasing associated mortality rate. In addition, growing number of research and development activities for effective treatments increasing the growth of global clostridium difficile diagnostic and treatment market. Furthermore, robust product pipeline of different therapies for the treatment of clostridium difficile is also fostering the growth of global clostridium difficile diagnostic and treatment market.

However, high cost of treatment and lack of awareness may hamper the market growth. In spite of that, PCR provides a rapid and sensitive screen for the determination of clonal relationships among C. difficile strains can offer more opportunities for the further growth of the global clostridium difficile diagnostic and treatment market.

North America is Expected to Dominate the Global Clostridium Difficile Diagnostic and Treatment Market

On the basis of region, the clostridium difficile diagnostic and treatment market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the clostridium difficile diagnostic and treatment market within the forecast period attributed to the technologically updated systems, higher consumption of junk food and rising cases of hospital acquired infection in this region. Europe is projected to capture the second largest share of clostridium difficile diagnostic and treatment market due to the new investments in processing capacity.

On Special Requirement Clostridium Difficile Diagnostic and Treatment Market Report is also available for below Regions and Country:

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA

Key Benefits of Global Clostridium Difficile Diagnostic and Treatment Market Report:

  • Global Clostridium Difficile Diagnostic and Treatment Market report covers in-depth historical and forecast analysis.
  • Global Clostridium Difficile Diagnostic and Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
  • Global Clostridium Difficile Diagnostic and Treatment Market report helps to identify opportunities in marketplace.
  • Global Clostridium Difficile Diagnostic and Treatment Market report covers extensive analysis of emerging trends and competitive landscape.


Frequently Asked Questions (FAQ) :
Clostridium Difficile Diagnostic and Treatment Market was valued at USD 2,571.22 million in 2021.
Clostridium Difficile Diagnostic and Treatment Market is expected to reach USD 5,663.87 million by 2028, with a CAGR of 11.9% during the forecast period
Merck & Co., Inc., Baxter International Inc., Sanofi S.A., Pfizer limited, Novartis, Astellas Pharma Inc., Eli Lilly and Company, AstraZeneca Plc., Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.), and Mylan N.V. and others
North America is Expected to Dominate the Global Clostridium Difficile Diagnostic and Treatment Market.
Increased prevalence of Clostridium difficile infection, robust product pipeline of different therapies for the treatment and growing R & D activities for effective treatments are anticipated to drive the growth of Global Clostridium Difficile Diagnostic and Treatment Market.



Interested in this report?

Clostridium Difficile Diagnostics and Treatment Market Size, Share, Industry Growth Analysis, And Growth By 2028

report cover

Table Of Content

  1. Chapter – Report Methodology
    Research Process
    Primary Research
    Secondary Research
    Market Size Estimates
    Data Triangulation
    Forecast Model
    USP’s of Report
    Report Description
  2. Chapter – Global Clostridium Difficile Diagnostics and Treatment Market Overview: Qualitative Analysis
    Market Introduction
    Executive Summary
    Global Clostridium Difficile Diagnostics and Treatment Market Classification
    Market Drivers
    Market Restraints
    Market Opportunity
    Antibacterial Drugs Market: Trends
    Porter’s Five Forces Analysis
    Bargaining Power of Suppliers
    Bargaining Power of Consumers
    Threat of New Entrants
    Threat of Substitute Product and Services
    Competitive Rivalry within the Industry
    Market Attractiveness Analysis
    Market Attractiveness Analysis by Segmentation
    Market Attractiveness Analysis by Region
  3. Chapter – Global Clostridium Difficile Diagnostics and Treatment Market Overview: Quantitative Analysis
    Global Antibacterial Drugs Market Consumption, Market Share ( %) and Growth Rate, 2015-2025
    Global Antibacterial Drugs Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2015-2025
  4. Chapter – Global Clostridium Difficile Diagnostics and Treatment Market Analysis: by Product Type
  5. Chapter – Global Clostridium Difficile Diagnostics and Treatment Market Analysis: by Test Type
  6. Chapter – Global Clostridium Difficile Diagnostics and Treatment Market Analysis: by Distribution Channel
  7. Chapter – Global Clostridium Difficile Diagnostics and Treatment Market Analysis: by Manufacturer
    Global Antibacterial Drugs Market Revenue (USD Million), by Manufacturer, 2015-2018
    Global Antibacterial Drugs Market Share (%), by Manufacturer, 2015-2018
    Global Antibacterial Drugs Market Price (USD/Unit), by Manufacturer, 2015-2018
    Global Antibacterial Drugs Market Revenue Growth Rate (%), by Manufacturer, 2015-2018
    Merger & Acquisition
    Collaborations and Partnership
    New Product Launch
  8. Chapter – Clostridium Difficile Diagnostics and Treatment Market: Regional Analysis
    North America
    North America Clostridium Difficile Diagnostics and Treatment Market Revenue (USD Million) and Growth Rate (%), 2015-2025.
    North America Clostridium Difficile Diagnostics and Treatment Market Revenue (USD Million) By Country, 2015-2025.
    North America Antibacterial Drugs Revenue Market Share (%) By Country, 2015-2025.
    North America Clostridium Difficile Diagnostics and Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2015-2025.
    North America Clostridium Difficile Diagnostics and Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2015-2025.
    North America Clostridium Difficile Diagnostics and Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2015-2025.
    Europe
    Asia Pacific
    Latin America
    Middle East & Africa
    Chapter – Company Profiles
    Merck & Co.
    Overview
    Financials
    Product portfolio
    Clostridium Difficile Diagnostics and Treatment Market Revenue (USD Million), Consumption and Market Share (%), 2014 – 2018
    Clostridium Difficile Diagnostics and Treatment Sales Market Share (%), 2014 – 2017
    Business strategy
    Recent developments
    Thermo Fisher Scientific Inc.
    Actelion Pharmaceuticals
    Baxter International Inc.
    Alere, Inc.
    Pfizer, Inc.
    Novartis AG
    Trinity Biotech
    Summit Therapeutics
    Sanofi S.A.
    AstraZeneca Plc.
    Others
  9. Chapter – Market Research and Findings

Clostridium Difficile Diagnostic and Treatment Market Size, Share, And Trends Analysis By Product Type: (Vancomycin, Metronidazole, Bezlotoxumab, Fidaxomicin) By Test: (Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Enzyme Immunoassays) By Distribution Channel: (Hospitals & Clinics, Diagnostic Laboratories, Pharmacies) Based On Region, And Segment Forecasts, 2022 - 2028

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.
Brandessence market research actively tracks, monitors, and analyses key industry trends in real-time via B2B surveys in 60 + countries and territories.

    Pricing


Looking for Regional Reports?